SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
E-cadherin gene methylation in lung cancer.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 9 citations in OpenAlex.
- Multidimensional exploration of the relationship between gut microbiota and colorectal cancer: focus on clinical tumorigenesis and treatment.Frontiers in immunology · 2026Review
- DNA Methylation in Lung Cancer: Predictive Biomarkers for Effective Immunotherapy.International journal of general medicine · 2025Review
- Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines.International journal of molecular sciences · 2020Article
- Article
- Rac3 Regulates Cell Invasion, Migration and EMT in Lung Adenocarcinoma through p38 MAPK Pathway.Journal of Cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
E-cadherin, a tumor repressor gene, has been shown to play an important role in maintaining the polarity and structural integrity of epithelial and is closely associated with tumorigenesis, invasion, and metastasis. The current study aimed to investigate the effects of E-cadherin methylation on lung cancer (LC) quantitatively through a meta-analysis. We searched electronic databases to identify eligible studies from their inception through September 30, 2013. Pooled odds ratio (OR) with 95 % confidence interval (CI) was used to assess the relationship between E-cadherin gene methylation and LC risk. A hazard ratio (HR) with 95 % CI was used to assess the impact of E-cadherin gene methylation on overall survival (OS) of LC patients. Seventeen studies comprising 983 LC cases and 669 controls met the inclusion criteria. Summary results revealed that hypermethylation frequencies in LC tissues were significantly higher than those in normal control tissues (OR = 4.11, 95 % CI 2.78-6.07, P < 0.001). Subgroup analysis indicated that higher methylation frequencies were observed in Asian population. Interestingly, we found that hypermethylation of E-cadherin was associated with significantly better survival with HR of 0.47 (95 % CI 0.31-0.71). This meta-analysis revealed that E-cadherin gene promoter methylation was associated with an increased risk of LC, especially in Asian population, and methylated E-cadherin predicted long survival in patients with LC. However, further studies with large numbers of patients will be needed to confirm the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.